Health

Results: 7081-7092 of 7359

Positive Results for Hexvix Phase III Clinical Trial in China Presented at the SIU 2023 Congress

PR Newswire associated0

Suvoda Introduces Advanced Drug Optimization For IRT to Improve Accuracy of Clinical Trial Drug Supply Management

AstraZeneca Awards Funding to Eight Innovative Research Projects From Early-Career Scientists Around the World in Second R&D Postdoctoral Challenge

STEMCELL Technologies, Canada’s largest biotechnology company, is releasing its first annual sustainability report. The report, entitled Toward Sustainable Science, provides a comprehensive look at STEMCELL’s environmental, social, and governance performance over the company’s 2023 Fiscal Year (July 1, 2022 through June 30, 2023). (Photo: Business Wire)

STEMCELL Technologies Releases “Toward Sustainable Science” Report

Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients

Care Access mobile research vehicle at Martha's Vineyard clinic. (Photo: Business Wire)

FDA Finds No Misconduct by Care Access in Pfizer’s Lyme Vaccine Trial

New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients

Galderma @ EADV 2023: Phase III Trials Demonstrate Nemolizumab’s Efficacy and Rapid Onset of Action in Atopic Dermatitis and Prurigo Nodularis

Alfasigma S.p.A. Tender Offer for Intercept Pharmaceuticals, Inc. Commences

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Illustrative example: cancer associated fibroblasts (CAFs) and the tumor microenvironment. (Photo: Business Wire)

SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers

Cellares Announces Expanded Agreement with Bristol Myers Squibb to Include Second CAR-T Program in Cellares’ Technology Adoption Partnership Program